表紙
市場調查報告書

遺傳性血管水腫 (HAE)的全球市場:產業分析,規模,佔有率,成長,趨勢,預測

Hereditary Angioedema Market (Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, & Other; Route of Administration; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 555315
出版日期 內容資訊 英文 153 Pages
商品交期: 最快1-2個工作天內
價格
遺傳性血管水腫 (HAE)的全球市場:產業分析,規模,佔有率,成長,趨勢,預測 Hereditary Angioedema Market (Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, & Other; Route of Administration; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2017年08月23日內容資訊: 英文 153 Pages
簡介

本報告提供全球遺傳性血管水腫 (HAE) 市場相關調查,提供市場概要,對市場成長的各種影響因素及市場機會分析,各藥物類別·給藥途徑·流通管道·地區/主要國家別趨勢與市場規模的變化與預測,競爭環境,並彙整主要企業的簡介等資訊。

第1章 序論

第2章 前提條件·調查手法

第3章 摘要整理:全球遺傳性血管水腫 (HAE) 市場

第4章 市場概要

  • 簡介
  • 市場概要
  • 市場動態
  • 遺傳性血管水腫 (HAE) 市場分析·預測
  • 市場展望
  • 波特的五力分析
  • 價值鏈分析
  • 開發平台分析
  • 孤兒藥
  • 疾病概要

第5章 全球遺傳性血管水腫 (HAE) 市場分析·預測:各類藥物

  • 簡介
  • 主要調查結果
  • 主要趨勢
  • 市場規模預測:各類藥物
    • C1酯酶抑製劑
    • 選擇性緩激肽B2受體抑制劑
    • 激肽釋放酶抑制劑
    • 其他
  • 比較矩陣
  • 市場魅力:各類藥物

第6章 全球遺傳性血管水腫 (HAE) 市場分析·預測:各給藥途徑

  • 簡介·定義
  • 主要調查結果
  • 主要趨勢
  • 市場規模預測:各給藥途徑
    • 靜脈內
    • 皮下注射
    • 口服
  • 比較矩陣
  • 市場魅力:各給藥途徑

第7章 全球遺傳性血管水腫 (HAE) 市場分析·預測:各流通管道

  • 簡介·定義
  • 主要調查結果
  • 主要趨勢
  • 市場規模預測:各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 比較矩陣
  • 市場魅力:各流通管道

第8章 全球遺傳性血管水腫 (HAE) 市場分析·預測:各地區

  • 主要調查結果
  • 主要趨勢
  • 市場規模預測:各地區
    • 北美
    • 歐洲
    • 其他
  • 市場魅力:各地區

第9章 北美的遺傳性血管水腫 (HAE) 市場分析·預測

  • 主要調查結果
  • 政策·規定
  • 市場概要
  • 市場規模·預測:各類藥物
  • 市場規模·預測:各給藥途徑
  • 市場規模·預測:各流通管道
  • 市場規模·預測:各國
  • 市場魅力分析

第10章 歐洲的遺傳性血管水腫 (HAE) 市場分析·預測

第11章 其他 (RoW)的遺傳性血管水腫 (HAE) 市場分析·預測

第12章 競爭情形

  • 市場佔有率分析
  • 市場參與企業:競爭矩陣
  • 企業簡介
    • Shire plc
    • CSL Limited
    • Pharming Group NV
    • Ionis Pharmaceuticals, Inc.
    • iBio Inc.
    • BioCryst Pharmaceuticals, Inc.

圖表

目錄

Title:
Hereditary Angioedema Market
(Drug Class - C1 Esterase Inhibitor (Cinryze, Berinert, and Ruconest), Selective Bradykinin B2 Receptor Antagonist (Firazyr), and Kallikrein Inhibitor (Kalbitor); Route of Administration - Intravenous, Subcutaneous Injection, and Oral; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Hereditary Angioedema Market: Scope and Methodology

This report on the global hereditary angioedema market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global hereditary angioedema market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global hereditary angioedema market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of product features of different types of drug class and various pipeline products. Additionally, market related factors such as rise in preference for self-administrable drugs, expiry of market exclusivity of certain drugs, projected launch of the drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Hereditary Angioedema Market: Segmentation

Hereditary Angioedema is a rare genetic disease that is caused by lack or abnormal functioning of the protein C1 inhibitor protein. Lack of functional C1 inhibitor protein leads to high volume of bradykinin, which triggers of blood vessels causing inflammation of body organs. HAE symptoms are often misdiagnosed for common allergies or abdominal pain. Many patients are hospitalized due to HAE attacks. HAE attack in upper airway have proven to be fatal if untreated on its emergence.

Based on drug class, the global hereditary angioedema market has been segmented into C1 esterase inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor others. The C1 esterase inhibitor is further segmented into drugs namely Cinryze, Berinert and Ruconest. The segment is anticipated to hold a significant share of the global market. The others segment is further sun segmented into conventional and pipeline products. The segment is projected to dominate the market during the forecast period due to launch of novel products.

Based on route of administration, the global hereditary angioedema market is segmented into intravenous, subcutaneous injections and oral. The subcutaneous injections is anticipated to dominate the market during the forecast period due to availability of approved drugs for acute HAE attack are administered subcutaneously, development of variants of Cinryze and Berinert that can be administered subcutaneously etc.

Based on the distribution channel, the global hereditary angioedema market is segmented into hospital pharmacies, retail pharmacies and others. Ever increasing number of retail pharmacies is attributed for the significant share of the segment in the global market.

Hereditary Angioedema Market: Geographical and Competitive Dynamics

Geographically, the global hereditary angioedema market has been segmented into six regions: North America, Europe, Asia Pacific and Rest of the World. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the hereditary angioedema market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc. and iBio, Inc.

The global hereditary angioedema market has been segmented as below:

Global Hereditary Angioedema Market, by Drug Class

  • C1 Esterase Inhibitor
    • Cinryze
    • Berinert
    • Ruconest
  • Selective Bradykinin B2 Receptor Antagonist
    • Firazyr
  • Kallikrein Inhibitor
    • Kalbitor
  • Others
    • Conventional Drugs (attenuated androgens, antifibrinolytic agents
    • Pipeline Products (DX-2930, BCX-7353)

Global Hereditary Angioedema Market, by Route of Administration

  • Intravenous
  • Subcutaneous Injection
  • Oral

Global Hereditary angioedema Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Hereditary Angioedema Market, by Geography

  • North America
  • Europe
  • Rest of the World

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Market Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
    • 4.3.4. Trends
  • 4.4. Hereditary Angioedema Market Analysis and Forecast, 2017 - 2025
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Market Outlook
  • 4.6. Porter's five forces analysis
  • 4.7. Value Chain Analysis
  • 4.8. Pipeline Analysis
  • 4.9. Orphan Drug Exclusivity Details
  • 4.10. Disease Overview

5. Global Hereditary Angioedema Market Analysis and Forecasts, By Drug Class

  • 5.1. Introduction & Definition
  • 5.2. Key Findings
  • 5.3. Key Trends
  • 5.4. Market Size (US$ Mn) Forecast By Drug Class
    • 5.4.1. C1 esterase inhibitor
      • 5.4.1.1. Cinryze
      • 5.4.1.2. Berinert
      • 5.4.1.3. Ruconest
    • 5.4.2. Selective bradykinin B2 receptor antagonist
      • 5.4.2.1. Firazyr
    • 5.4.3. Kallikrein inhibitor
      • 5.4.3.1. Kalbitor
    • 5.4.4. Others
      • 5.4.4.1. Conventional Drugs
      • 5.4.4.2. Pipeline Drugs
  • 5.5. Comparison Matrix
  • 5.6. Market Attractiveness By Drug Class

6. Global Hereditary Angioedema Market Analysis and Forecasts, By Route of Administration

  • 6.1. Introduction & Definition
  • 6.2. Key Findings
  • 6.3. Market Size (US$ Mn) Forecast By Route of Administration
    • 6.3.1. Intravenous
    • 6.3.2. Subcutaneous injection
    • 6.3.3. Oral
  • 6.4. Comparison Matrix
  • 6.5. Market Attractiveness By Route of Administration

7. Global Hereditary Angioedema Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings
  • 7.3. Key Trends
  • 7.4. Market Size (US$ Mn) Forecast By Distribution Channel
    • 7.4.1. Hospital pharmacies
    • 7.4.2. Retail pharmacies
    • 7.4.3. Others
  • 7.5. Comparison Matrix
  • 7.6. Market Attractiveness By Distribution Channel

8. Global Hereditary Angioedema Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Key Trends
  • 8.3. Market Size (US$ Mn) Forecast By Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Rest of the World
  • 8.4. Market Attractiveness By Region

9. North America Hereditary Angioedema Market Analysis and Forecast

  • 9.1. Key Findings
  • 9.2. Policies and Regulations
  • 9.3. Market Overview
  • 9.4. Market Size (US$ Mn) Forecast By Drug Class
    • 9.4.1. C1 esterase inhibitor
      • 9.4.1.1. Cinryze
      • 9.4.1.2. Berinert
      • 9.4.1.3. Ruconest
    • 9.4.2. Selective bradykinin B2 receptor antagonist
      • 9.4.2.1. Firazyr
    • 9.4.3. Kallikrein inhibitor
      • 9.4.3.1. Kalbitor
    • 9.4.4. Others
      • 9.4.4.1. Conventional Drugs
      • 9.4.4.2. Pipeline Drugs
  • 9.5. Market Size (US$ Mn) Forecast By Route of Administration
    • 9.5.1. Intravenous
    • 9.5.2. Subcutaneous injection
    • 9.5.3. Oral
  • 9.6. Market Size (US$ Mn) Forecast By Distribution Channel
    • 9.6.1. Hospital pharmacies
    • 9.6.2. Retail pharmacies
    • 9.6.3. Others
  • 9.7. Market Size by Value (US$ Mn) Forecast, By Country
    • 9.7.1. U.S.
    • 9.7.2. Canada
  • 9.8. Market Attractiveness Analysis
    • 9.8.1. By Drug Class
    • 9.8.2. By Route of Administration
    • 9.8.3. By Distribution Channel
    • 9.8.4. By Country

10. Europe Hereditary Angioedema Market Analysis and Forecast

  • 10.1. Key Findings
  • 10.2. Policies and Regulations
  • 10.3. Market Overview
  • 10.4. Market Size (US$ Mn) Forecast By Drug Class
    • 10.4.1. C1 esterase inhibitor
      • 10.4.1.1. Cinryze
      • 10.4.1.2. Berinert
      • 10.4.1.3. Ruconest
    • 10.4.2. Selective bradykinin B2 receptor antagonist
      • 10.4.2.1. Firazyr
    • 10.4.3. Others
      • 10.4.3.1. Conventional Drugs
      • 10.4.3.2. Pipeline Drugs
  • 10.5. Market Size (US$ Mn) Forecast By Route of Administration
    • 10.5.1. Intravenous
    • 10.5.2. Subcutaneous injection
    • 10.5.3. Oral
  • 10.6. Market Size (US$ Mn) Forecast By Distribution Channel
    • 10.6.1. Hospital pharmacies
    • 10.6.2. Retail pharmacies
    • 10.6.3. Others
  • 10.7. Market Size by Value (US$ Mn) Forecast, By Country
    • 10.7.1. Germany
    • 10.7.2. U.K.
    • 10.7.3. France
    • 10.7.4. Spain
    • 10.7.5. Italy
    • 10.7.6. Rest of Europe
  • 10.8. Market Attractiveness Analysis
    • 10.8.1. By Drug Class
    • 10.8.2. By Route of Administration
    • 10.8.3. By Distribution Channel
    • 10.8.4. By Country / Sub-region

11. Rest of The World Hereditary Angioedema Market Analysis and Forecast

  • 11.1. Key Findings
  • 11.2. Policies and Regulations
  • 11.3. Market Overview
  • 11.4. Market Size (US$ Mn) Forecast By Drug Class
    • 11.4.1. C1 esterase inhibitor
      • 11.4.1.1. Cinryze
      • 11.4.1.2. Berinert
      • 11.4.1.3. Ruconest
    • 11.4.2. Selective bradykinin B2 receptor antagonist
      • 11.4.2.1. Firazyr
    • 11.4.3. Kallikrein inhibitor
      • 11.4.3.1. Kalbitor
    • 11.4.4. Others
      • 11.4.4.1. Conventional Drugs
      • 11.4.4.2. Pipeline Drugs
  • 11.5. Market Size (US$ Mn) Forecast By Route of Administration
    • 11.5.1. Intravenous
    • 11.5.2. Subcutaneous injection
    • 11.5.3. Oral
  • 11.6. Market Size (US$ Mn) Forecast By Distribution Channel
    • 11.6.1. Hospital pharmacies
    • 11.6.2. Retail pharmacies
    • 11.6.3. Others
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Distribution Channel

12. Competition Landscape

  • 12.1. Market Share Analysis
  • 12.2. Market Player - Competition Matrix (By Tier and Size of companies)
  • 12.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 12.3.1. Shire plc
      • 12.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.1.2. Product Portfolio
      • 12.3.1.3. SWOT Analysis
      • 12.3.1.4. Financial Overview
      • 12.3.1.5. Strategic Overview
    • 12.3.2. CSL Limited
      • 12.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.2.2. Product Portfolio
      • 12.3.2.3. SWOT Analysis
      • 12.3.2.4. Financial Overview
      • 12.3.2.5. Strategic Overview
    • 12.3.3. Pharming Group NV
      • 12.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.3.2. Product Portfolio
      • 12.3.3.3. SWOT Analysis
      • 12.3.3.4. Financial Overview
      • 12.3.3.5. Strategic Overview
    • 12.3.4. Ionis Pharmaceuticals, Inc.
      • 12.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.4.2. Product Portfolio
      • 12.3.4.3. SWOT Analysis
      • 12.3.4.4. Financial Overview
      • 12.3.4.5. Strategic Overview
    • 12.3.5. iBio Inc.
      • 12.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.5.2. Product Portfolio
      • 12.3.5.3. SWOT Analysis
      • 12.3.5.4. Financial Overview
      • 12.3.5.5. Strategic Overview
    • 12.2.6. BioCryst Pharmaceuticals, Inc.
      • 12.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.3.6.2. Product Portfolio
      • 12.3.6.3. SWOT Analysis
      • 12.3.6.4. Financial Overview
      • 12.3.6.5. Strategic Overview

List of Tables

  • Table 01: Pipeline Analysis, by Phase III
  • Table 02: Pipeline Analysis, By Phase II and Phase I
  • Table 03: Pipeline Analysis, By Preclinical Trial (1/2)
  • Table 04: Pipeline Analysis, By Preclinical Trial (2/2)
  • Table 05: Orphan Drug Exclusivity (1/3)
  • Table 06: Orphan Drug Exclusivity (2/3)
  • Table 07: Orphan Drug Exclusivity (3/3)
  • Table 08: Disease Overview by Type of HAE
  • Table 09: Reported and Estimated Cases of HAE, By Country
  • Table 10: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 11: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015-2025
  • Table 12: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015-2025
  • Table 13: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • Table 14: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 15: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 16: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 17: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015-2025
  • Table 18: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015-2025
  • Table 19: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • Table 20: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 21: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015-2025
  • Table 22: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 23: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 esterase inhibitor, 2015-2025
  • Table 24: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015-2025
  • Table 25: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • Table 26: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 27: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015-2025
  • Table 28: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 29: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - C1 Esterase Inhibitor, 2015-2025
  • Table 30: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015-2025
  • Table 31: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • Table 32: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Hereditary Angioedema, by Drug Class, Market Size (US$ Mn), 2016 (A)
  • Figure 02: Global Hereditary Angioedema Market Revenue (%), by Route of Administration, 2016 (A)
  • Figure 03: Global Hereditary Angioedema Market Revenue (%), by Region, 2016 (A)
  • Figure 04: Opportunity Map, By Drug Class 2016
  • Figure 05: Opportunity Map, By Route of Administration and Distribution Channel 2016
  • Figure 06: Global Hereditary Angioedema Market - Key Industry Developments
  • Figure 07: Global Hereditary Angioedema Market - Key Drivers and Restraints
  • Figure 08: Global Hereditary Angioedema Market - Opportunity Analysis
  • Figure 09: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 10: Porter's Five Forces Analysis
  • Figure 11: Global Hereditary Angioedema Market - Value Chain Analysis
  • Figure 12: Market Value Share, by Drug Class (2016)
  • Figure 13: Market Value Share, by Route of Administration (2016)
  • Figure 14: Market Value Share, by Distribution Channel (2016)
  • Figure 15: Global Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 16: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2015-2025
  • Figure 17: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2015-2025
  • Figure 18: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2015-2025
  • Figure 19: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015-2025
  • Figure 20: Global Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
  • Figure 21: Global Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
  • Figure 22: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2015-2025
  • Figure 23: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2015-2025
  • Figure 24: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015-2025
  • Figure 25: Global Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
  • Figure 26: Global Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 27: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015-2025
  • Figure 28: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015-2025
  • Figure 29: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015-2025
  • Figure 30: Global Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 31: Global Hereditary Angioedema Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 32: Global Hereditary Angioedema Market Attractiveness Analysis, by Region
  • Figure 33: North America Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 34: North America Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 35: North America Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
  • Figure 36: North America Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 37: North America Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 38: North America Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
  • Figure 39: North America Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
  • Figure 40: North America Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
  • Figure 41: North America Market Attractiveness Analysis, by Country
  • Figure 42: Europe Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 43: Europe Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 44: Europe Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
  • Figure 45: Europe Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 46: Europe Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 47: Europe Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
  • Figure 48: Europe Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
  • Figure 49: Europe Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
  • Figure 50: Europe Market Attractiveness Analysis, by Country
  • Figure 51: Rest of the World Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 52: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 53: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
  • Figure 54: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 55: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
  • Figure 56: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
  • Figure 57: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
  • Figure 58: Global Hereditary Angioedema Market Share Analysis, by Company (2016)
  • Figure 59: Shire Plc. Breakdown of Net Sales, by Segment, 2016
  • Figure 60: Shire Plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 61: CSL Limited Breakdown of Net Sales, by Region, 2015
  • Figure 62: CSL Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2012-2015
  • Figure 63: Pharming Group NV Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
  • Figure 64: Ionis Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 65: iBio, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
  • Figure 66: BioCryst Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016